bluebird bio Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Good morning, everybody. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Very pleased to have bluebird with us for the next session.
Quickly before we get started, I need to read a disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/research disclosures.
And with that, I'm going to turn it over to Andrew to make some opening comments. And then we can get right into Q&A.
Hi, everyone. So for those of you who are used to see Nick Leschly as the CEO of bluebird, I'm Andrew Obenshain and I'm currently the President of the Rare Disease Division. And come our split in October, I will become the CEO of bluebird, so a new face for many of you I'm sure.
I am joined
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |